Ocuphire Pharma Appoints New Director

TL;DR

Ocuphire Pharma adds Dr. Van Sickle to its board, signaling potential strategic shifts.

AI Summary

Ocuphire Pharma, Inc. announced on April 11, 2024, a change in its board of directors. Specifically, Dr. Robert L. Van Sickle has been appointed to the Board of Directors, effective immediately. This appointment is part of the company's ongoing efforts to strengthen its leadership and strategic direction.

Why It Matters

The addition of a new director can signal strategic shifts or a focus on specific areas of expertise that may impact the company's future development and market performance.

Risk Assessment

Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.

Key Players & Entities

• Ocuphire Pharma, Inc. (company) — Registrant
• Dr. Robert L. Van Sickle (person) — Appointed to the Board of Directors
• April 11, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share OCUP The Nasdaq
• $39,583.00 — ill be paid a monthly consulting fee of $39,583.00 and an award of 32,000 restricted stock
• $1.79 — mmon stock on April 11, 2024, which was $1.79 (the " Options "). The RSUs will vest o

Filing Documents

• ef20027138_8k.htm (8-K) — 30KB
• ef20027138_ex10-1.htm (EX-10.1) — 150KB
• 0001140361-24-020320.txt ( ) — 343KB
• ocup-20240411.xsd (EX-101.SCH) — 4KB
• ocup-20240411_lab.xml (EX-101.LAB) — 21KB
• ocup-20240411_pre.xml (EX-101.PRE) — 16KB
• ef20027138_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 11, 2024, Ocuphire Pharma, Inc., a Delaware corporation (the " Company "), entered into a Consulting Agreement (the " Consulting Agreement "), pursuant to which Jay Pepose, M.D., a director sitting on the Company's board of directors, agreed to serve as a consultant of the Company. Pursuant to the Consulting Agreement, Dr. Pepose will be paid a monthly consulting fee of $39,583.00 and an award of 32,000 restricted stock units (" RSUs "), as well as stock options to purchase 48,000 shares of the Company's common stock, with an exercise price based on the closing price of the common stock on April 11, 2024, which was $1.79 (the " Options "). The RSUs will vest on April 11, 2025, subject to Dr. Pepose's continued service over that period. The Options will vest in 12 equal monthly installments beginning on May 11, 2024, subject to Dr. Pepose's continued service over that period . The Consulting Agreement will terminate on April 11, 2025 unless mutually extended. The foregoing summary of the Consulting Agreement is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 10.1 Consulting Agreement between Ocuphire Pharma, Inc. and Jay Pepose, M.D., dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 17, 2024 OCUPHIRE PHARMA, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR